Alzheimer S Disease (AD)
Annexes to 6.11: Alzheimer's Disease
Priority Medicines for Europe and the World
"A Public Health Approach to Innovation"
Background Paper for Review
Annexes
to
Alzheimer’s Disease
“Opportunities to Address Pharmaceutical Gaps”
By Saloni Tanna, Pharm.D; MPH
24 August 2004
Please send comments to:
Dr Richard Laing
6.11-1
Annexes to 6.11: Alzheimer's Disease
Table of ContentsAnnex 1. Resource List 3
Annex 2: FP5 Projects for Alzheimer’s Disease
(Records were found in the Projects Database) 4
Annex 1. Resource List
This list identifies sources for the Differential Diagnosis of Alzheimer’s Disease, which is often part of the diagnosis Algorithm to confirm a diagnosis of Alzheimer’s disease.[1]
§ Mini-Mental Status Examination
Folstein, M.F., Folstein, S.E., and McHugh P.R. “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research (November 1975), vol. 12 (3): 189-98.
Cockrell, J. R. and M.F. Folstein. Mini-Mental State Examination (MMSE). Psychopharmacology Bulletin (1988), vol. 24 (4): 689-92.
§ Physical Self-Maintenance Scale
Lawton, M., Brody, E. “Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living.” The Gerontologist. 1969, 9:179-86.
§ DSM-IV Criteria
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition. Washington, D.C.: American Psychiatric Press, 1994.
§ AHRQ Guidelines (Agency for Healthcare Research and Quality)
Costa, P. T. Jr., et al. Early identification of Alzheimer’s disease and related dementias. Clinical practice guidelines, quick reference guide for clinicians, no. 19. Rockville, Md.: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1996.
§ American Academy of Neurology (AAN) Guidelines
American Academy of Neurology. Practice parameters for detection, diagnosis, and management of dementia (summary statements). Neurology (May 8, 2001), vol. 56: 1133-1142, 1143-1153, 1154-1166.
§ National Institute of Neurological Disorders and Stroke (NINDS) Criteria
Roman, G. C., et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop. Neurology (February 1993), vol. 43 (2): 250-60.
§ National Institute of Neurological Communicative Disorders and Stroke (NINCDS) and the Alzheimer Disease and Related Disorders Association Criteria
McKhann, G., et al. Mental and clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology (July 1984), vol. 34 (7): 939-44.
Annex 2: FP5 Projects for Alzheimer’s Disease(Records were found in the Projects Database)
Apoe and inflammatory responses to brain injury in Alzheimer’s diseaseFP5 Program Acronym: HUMAN POTENTIAL
Project Reference: HPMF-CT-1999-00136
Microdomains, Lipid Rafts and Caveolae
FP5 Program Acronym: HUMAN POTENTIAL
Project Reference: HPCF-CT-2000-00180-02
Project URL: http://www.esf.org/euresco/03/lc03166
Bioflavonoïds and polyphenols in health and disease
FP5 Programme Acronym: HUMAN POTENTIAL
Project Reference: HPCF-CT-1999-00167-01
Project URL: http://imoax1.unimo.it~sfrr/dinard.htm
Microdomains, Lipid Rafts and Caveolae
FP5 Program Acronym: HUMAN POTENTIAL
Project Reference: HPCF-CT-2000-00180-01
Project URL: http://www.esf.org/euresco/03/lc03166
Neural Mechanisms of Learning and Memory
FP5 Program Acronym: HUMAN POTENTIAL
Project URL: http://www.esf.org/euresco/02/lc02048
Neural Mechanisms of Learning and Memory
FP5 Program Acronym: HUMAN POTENTIAL
Project Reference: HPCF-CT-2001-00034-01
Project URL: http://www.esf.org/euresco/02/lc02048
Protein aggregation - an interdisciplinary school
FP5 Program Acronym: HUMAN POTENTIAL
Project Reference: HPCF-CT-2001-00426-01
Project URL: http://lxmi.mi.infn.it/tiana/leshouches/
Characterisation of ltrpc2 physiology and its role during metabolic stress
FP5 Programme Acronym: HUMAN POTENTIAL
Project Reference: HPMI-CT-2002-00170
Project Acronym: LTRPC2PHYSIOL
Role of Peroxisome Proliferator-Activated Receptors (PPARs) in Neurodegenerative Disease
FP5 Programme Acronym: HUMAN POTENTIAL
Project Reference: HPMI-CT-2002-00158
Baltic Summer School 2003: Neurodegenerative diseases: mechanisms and principles of rational treatment
FP5 Programme Acronym: HUMAN POTENTIAL
Project Reference: HPCF-CT-2002-00470-01
Project URL: http://www.uni-kiel.de/neurologie/
Properties and functions of neuronal KCNQ/m-type potassium channels mutated in human disease
FP5 Programme Acronym: LIFE QUALITY
Project Reference: QLG3-CT-1999-00827
Project Acronym: KCNQ CHANNELS
The fe65-app-x11 protein-protein interaction network: towards the generation of new molecular tools for Alzheimer's disease diagnosis and therapy
FP5 Program Acronym: LIFE QUALITY
Project Reference: QLK6-CT-1999-02238
Project Acronym: GRASPING ALZHEIMER
Microglial activation in neurodegeneration in Alzheimer's disease: a therapeutical target?
FP5 Program Acronym: LIFE QUALITY
Project Reference: QLK6-CT-1999-02004
Project Acronym: MANAD
Validation of single and multiple mice models for Alzheimer's disease
FP5 Program Acronym: LIFE QUALITY
Project Reference: QLK6-CT-1999-02189
Project Acronym: APP-PS
Interactions between oxidative stress and the activation of mitogenic signalling in Alzheimer's disease
FP5 Program Acronym: LIFE QUALITY
Project Reference: QLK6-CT-1999-02112
Project Acronym: OXIDANT STRESS IN AD
Enhancement of clinical value of functional imaging through automated removal of partial volume effect
FP5 Program Acronym: LIFE QUALITY
Project Reference: QLG3-CT-2000-00594
Project Acronym: PVEOUT
Nutritional health-sustaining factors and determinants of healthy aging: oxidative stress-related biomakers of successful aging and age-related diseases
FP5 Program Acronym: LIFE QUALITY
Project Reference: QLK6-CT-1999-51332
Identification of tau-interacting proteins facilitating tau filament formation
FP5 Program Acronym: LIFE QUALITY
Project Reference: QLK6-CT-1999-51519
Biological nuclear magnetic resonance in the post-genomic era
FP5 Program Acronym: LIFE QUALITY
Project Reference: QLK4-CT-1999-51551
Neuroreceptor changes in mild cognitive impairment
FP5 Program Acronym: LIFE QUALITY
Project Reference: QLK6-CT-2000-00502
Properties and functions of neuronal KCNQ/m-type potassium channels mutated in human disease
FP5 Program Acronym: LIFE QUALITY
Project Reference: QLG3-CT-1999-00827
Project Acronym: KCNQ CHANNELS
Enabling Technologies for Persons with Dementia
FP5 Program Acronym: LIFE QUALITY
Project Reference: QLK6-CT-2000-00653
Project Acronym: ENABLE
Enhancement of clinical value of functional imaging through automated removal of partial volume effect
FP5 Program Acronym: LIFE QUALITY
Project Reference: QLG3-CT-2000-00594
Project Acronym: PVEOUT
6.11-1
Annexes to 6.11: Alzheimer's Disease
Early Diagnosis of Alzheimer's Disease and Related DementiaFP5 Program Acronym: LIFE QUALITY
Project Reference: QLK3-CT-2001-02362
Project Acronym: DIADEM 59014
Validation of single and multiple mice models for Alzheimer's disease
FP5 Program Acronym: LIFE QUALITY
Project Reference: QLK6-CT-1999-02189
Project Acronym: APP-PS 52701
Kainate and ampa receptor trafficking and recycling at brain synapses
FP5 Program Acronym: LIFE QUALITY
Project Reference: QLG3-CT-2001-02089
Project Acronym: KAR-TRAP 61249
European network to develop new therapeutic strategies for Parkinson's disease using lentiviral vector technology
FP5 Program Acronym: LIFE QUALITY
Project Reference: QLK3-CT-2002-02114
Project Acronym: NEUROPARK
The fe65-app-x11 protein-protein interaction network: towards the generation of new molecular tools for Alzheimer's disease diagnosis and therapy
FP5 Program Acronym: LIFE QUALITY
Project Reference: QLK6-CT-1999-02238
Project Acronym: GRASPING ALZHEIMER 52676
6.11-1
[1] http://www.alz.org/Health/Diagnose/overview.asp. Alzheimers Association. Diagnosis. Last Accessed July 27, 2004.